Article
Pharmacology & Pharmacy
Rachel A. Bender Ignacio, David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, Michael D. Hughes, Joseph J. Eron, Judith S. Currier, Davey Smith, Kara W. Chew, Michael Gibbs, Courtney Fletcher
Summary: This study evaluated the pharmacokinetics of AZD7442 in different administration routes and found that the thigh intramuscular injection had similar serum concentrations compared to intravenous injection in symptomatic adults with COVID-19. Thigh injection can provide consistent antibody exposure and improve convenience of use.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Evgenia Aga, Michael Gibbs, Herve Tchouakam Kouekam, Eva Johnsson, Mark T. Esser, Keila Hoover, Gene Neytman, Matthew Newell, Eric S. Daar, William Fischer, Courtney V. Fletcher, Jonathan Z. Li, Alexander L. Greninger, Robert W. Coombs, Michael D. Hughes, Davey Smith, David Alain Wohl
Summary: These two clinical trials showed that tixagevimab and cilgavimab monoclonal antibodies were safe and effective for treating early COVID-19, but did not change the time to symptom improvement. The treatment outcomes were better for the intramuscular injection.
Review
Pharmacology & Pharmacy
Toshihiko Tashima
Summary: Alzheimer's disease is a neurodegenerative disease with increasing global prevalence, for which the etiology and pathological mechanisms are not yet clear. There are currently no definitive therapies available for AD, although targeting tau and A beta have shown promise as treatment approaches.
Article
Pharmacology & Pharmacy
Zhidi Pan, Jie Chen, Xiaodong Xiao, Yueqing Xie, Hua Jiang, Baohong Zhang, Huili Lu, Yunsheng Yuan, Lei Han, Yuexian Zhou, Huifang Zong, Lei Wang, Rui Sun, Jianwei Zhu
Summary: T cell engaging bispecific antibody (TCB) is an effective immunotherapy that redirects CD3(+) T cells to eliminate tumor cells without relying on T cell receptor specificity. In this study, a novel TCB targeting tissue factor (TF-TCB) was designed and characterized for the treatment of TF-positive tumors. TF-TCB induced robust T cell activation and proliferation, and effectively lysed tumor cells both in vitro and in vivo. Tumor growth was strongly inhibited by TF-TCB, and T cell infiltration into tumors was induced during the treatment. Combination with immune checkpoint inhibitors further improved the efficacy of TF-TCB.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Immunology
James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong
Summary: P-cadherin is overexpressed in solid tumors, and PF-06671008 shows antitumor activity by engaging P-cadherin and CD3 epsilon. This phase 1 study evaluates the safety and tolerability of PF-06671008 and provides insights into managing immune-related adverse events. Limited antitumor activity and cytokine release syndrome were observed.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Emily Capone, Rossano Lattanzio, Fabio Gasparri, Paolo Orsini, Cosmo Rossi, Valentina Iacobelli, Vincenzo De Laurenzi, Pier Giorgio Natali, Barbara Valsasina, Stefano Iacobelli, Gianluca Sala
Summary: The ADC EV20/NMS-P945, developed by combining an anti-HER-3 antibody with a DNA alkylating agent, showed target-dependent cytotoxic activity against various tumor cells in vitro and therapeutic effectiveness in mouse xenograft tumor models. Pharmacokinetics and toxicological studies in monkeys indicated that this ADC is well tolerated and has favorable half-life and stability, supporting its further clinical development as a therapeutic agent for HER-3-expressing malignancies.
Review
Biochemistry & Molecular Biology
Ayuob Aghanejad, Samad Farashi Bonab, Maryam Sepehri, Fatemeh Sadat Haghighi, Ali Tarighatnia, Christopher Kreiter, Nader D. Nader, Mohammad Reza Tohidkia
Summary: Monoclonal antibodies have been considered a promising tool in cancer therapy and the study of the tumor microenvironment has become increasingly important. Innovative strategies targeting the vasculature system, immune system, stroma-based growth signals, and cancer stem cells have been highlighted as ways to indirectly destroy tumor cells.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Oncology
Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E. Mudd, Helen Harrison, Paul J. Beswick, Katerine Van Rietschoten, Sophie M. Watcham, Heather S. Scott, Amy N. Brown, Peter U. Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J. Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee
Summary: Nectin-4 is overexpressed in multiple tumor types, and BT8009, a new drug targeting Nectin-4, exhibits significant antitumor activity and good tolerability in solid tumors expressing Nectin-4.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Patrick Schoeffski, Ahmad Awada, Anne-Marie de la Bigne, Zakia Felloussi, Mike Burbridge, Frederique Cantero, Riccardo Colombo, Sara Maruzzelli, Katia Ammattatelli, Maja de Jonge, Philippe Aftimos, Herlinde Dumez, Stefan Sleijfer
Summary: S81694 can be safely administered as a single agent in adults with solid tumors at a dose of up to 135 mg/m(2)/week on days 1,8,15 of a 28-day cycle, without reaching the MTD.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, Kazuteru Fukasawa, Haruyasu Murakami
Summary: Telisotuzumab vedotin demonstrated manageable safety profile and antitumor activity in Japanese patients with advanced solid tumors, with the recommended phase 2 dose confirmed as 2.7 mg/kg every 3 weeks.
Article
Oncology
Lisa A. King, Elisa C. Toffoli, Myrthe Veth, Victoria Iglesias-Guimarais, Manon C. Slot, Derk Amsen, Rieneke van de Ven, Sarah Derks, Marieke F. Fransen, Jurriaan B. Tuynman, Thilo Riedl, Rob C. Roovers, Anton E. P. Adang, Jurjen M. Ruben, Paul W. H. I. Parren, Tanja D. de Gruijl, Hans J. van der Vliet
Summary: This study assessed the antitumor activity and safety of a bispecific antibody that activates Vy9V82 T cells. In vitro, in vivo, and ex vivo experiments were conducted, and safety was evaluated in nonhuman primates. The findings demonstrated the potential of the antibody to activate Vy9V82 T cells for antitumor activity and its acceptable safety profile, providing a solid basis for further testing in patients with EGFR-positive malignancies.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Margaretha A. Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Kueffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Stroebel, Kai Stuehler, Daniel Nettersheim
Summary: This study identified a novel CLDN6-ADC for targeting germ cell tumors (GCT) and discovered pharmacological inhibitors that block FGF, VGF, PDGF, mTOR, CHEK1, AURKA, or PARP signaling for the treatment of refractory yolk-sac tumors (YST). Furthermore, the study shed light on the mechanisms of therapy resistance in YST.
MOLECULAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
Summary: The newly developed bispecific antibody AFM24 shows high efficacy against tumor cells expressing varying levels of EGFR, without causing significant toxicity. This antibody demonstrates potent cell killing effects both in vitro and in vivo, indicating its potential as a promising cancer therapy.
Article
Oncology
Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Summary: NEO-201 is a humanized mAb generated against tumor-associated antigens in patients with colorectal cancer. The phase I trial showed that NEO-201 was safe and well tolerated, with neutropenia being the most common adverse event. The study also observed a reduction in the percentage of regulatory T cells after NEO-201 treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Aung Naing, Fiona Thistlethwaite, Elisabeth G. E. De Vries, Ferry A. L. M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Manreet Randhawa, Greg Durm, Marta Gil-Martin, Mark Stroh, Alison L. Hannah, Hendrik-Tobias Arkenau, Alexander Spira
Summary: Probody therapeutics show potential safety and anti-tumor activity in the treatment of tumors, with low immune-related toxicity and signs of efficacy even in patients with low PD-L1 expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
